SCHEMBL3030338

SCHEMBL3030338

CCOC(=O)c1cnn(-c2cccc(-c3cccc(C(F)(F)F)c3OCc3ccc(C4CN(C(=O)OC(C)(C)C)C4)cc3)n2)c1C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GUCY1A1 Q02108 16/20 0.65
GUCY1B1 Q02153 16/20 0.65
KDM4E B2RXH2 3/20 0.41
HPGD P15428 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3039341 0.95 GUCY1A1 (0.69) GUCY1A1GUCY1B1POLBMEN1ALDH1A1
SCHEMBL3034612 0.95 GUCY1A1 (0.69) GUCY1A1GUCY1B1POLBMEN1ALDH1A1
SCHEMBL16855181 0.94 GUCY1A1 (0.74) GUCY1A1GUCY1B1POLBMEN1ALDH1A1
SCHEMBL3024617 0.90 GUCY1A1 (0.52) GUCY1A1GUCY1B1
SCHEMBL3038213 0.88 GUCY1A1 (0.66) GUCY1A1GUCY1B1POLBMEN1ALDH1A1
SCHEMBL3044929 0.88 GUCY1A1 (0.66) GUCY1A1GUCY1B1POLBMEN1ALDH1A1
SCHEMBL16835707 0.87 GUCY1A1 (0.65) GUCY1A1GUCY1B1
SCHEMBL16835706 0.87 GUCY1A1 (0.62) GUCY1A1GUCY1B1
SCHEMBL3041495 0.87 GUCY1A1 (0.55) GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1
SCHEMBL18044332 0.87 GUCY1A1 (0.55) GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401265-B1 DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES MERCK SHARP & DOHME (US) 2016-09-14 EP disclosed
US-8507512-B2 Soluble guanylate cyclase activators MERCK SHARP & DOHME CORP. (US) 2013-08-13 US disclosed
US-20100216764-A1 Soluble Guanylate Cyclase Activators MERCK SHARP & DOHME LLC 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216764-A1 Soluble Guanylate Cyclase Activators GUCY1B1, GUCY1A1, GUCY1A2 GUCY1A1 2/4885GUCY1B1 1/4885KDM4E 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.